Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,899 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy: A Multicenter Double-Blind Randomized Controlled Trial.
Huang HY, Lin YP, Wei H, Fu Y, Zhou YH, Fang ZH, Qiu XT, Wang M, Li QB, Li SS, Wang SD, Dai F, Liu ZJ, Zhao L, Wen JX, Wu LY, Zeng HY, Zhang JM, Lu QY, He L, Song W, Sun L, Luo LL, He JL, Xie WW, Liang QS, Huang Y, Zhu SL, Long JE, Gao ZJ, Wen ZH, Li CJ, Ouyang WW, Li G, Wu MH, Li AX, Huang JZ, Paul SK, Tang XY, Fan GJ. Huang HY, et al. Among authors: li ss, li qb, li g, li cj, li ax. Chin J Integr Med. 2024 Mar;30(3):195-202. doi: 10.1007/s11655-024-3900-8. Epub 2024 Feb 20. Chin J Integr Med. 2024. PMID: 38374490 Clinical Trial.
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Cai L, et al. Among authors: li ss, li sq, li ry, li cx. Chin Med J (Engl). 2020 Nov 20;133(22):2665-2673. doi: 10.1097/CM9.0000000000001163. Chin Med J (Engl). 2020. PMID: 33060370 Free PMC article. Clinical Trial.
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J. Cai L, et al. Br J Dermatol. 2024 Aug 14;191(3):336-343. doi: 10.1093/bjd/ljae062. Br J Dermatol. 2024. PMID: 38366639 Clinical Trial.
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.
Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J. Yan K, et al. J Am Acad Dermatol. 2025 Jan;92(1):92-99. doi: 10.1016/j.jaad.2024.09.031. Epub 2024 Sep 26. J Am Acad Dermatol. 2025. PMID: 39332633 Clinical Trial.
Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.
Li J, Liang Y, Feng W, Deng L, Fang H, Ji C, Lin Y, Zhang F, Xia R, Zhang C, Guo S, Lin M, Li Y, Zhang S, Kang X, Chen L, Song Z, Yao X, Li C, Han X, Guo G, Guo Q, Duan X, Li J, Su J, Li S, Sun Q, Tao J, Ding Y, Deng D, Li F, Suo H, Wu S, Qiu J, Luo H, Li L, Li R. Li J, et al. Chin Med J (Engl). 2025 Aug 20;138(16):2040-2042. doi: 10.1097/CM9.0000000000003593. Epub 2025 Jun 6. Chin Med J (Engl). 2025. PMID: 40474341 Free PMC article. No abstract available.
Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.
Cai L, Li C, Li S, Zhang X, Wang G, Yu J, Huang K, Fang H, Ding Y, Wang J, Jiang C, Lu Q, Tao J, Zhang J. Cai L, et al. Dermatol Ther (Heidelb). 2025 Oct;15(10):2803-2816. doi: 10.1007/s13555-025-01450-x. Epub 2025 Jun 15. Dermatol Ther (Heidelb). 2025. PMID: 40517362 Free PMC article.
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial.
Zhang J, Zhou C, Miao G, Zhang S, Duan X, Wu L, Zhang G, Dang N, Ding Y, Han H, Wei A, Yang B, Li L, Li S, Dai X, Zhang J, Lei T, Yan W, Zhang L, Meng Z, Chen R, Song Q, Wang L, Wang W, Hu X, Xiang Z, Shi Z, Zhang L. Zhang J, et al. J Am Acad Dermatol. 2025 Sep 16:S0190-9622(25)02824-5. doi: 10.1016/j.jaad.2025.09.036. Online ahead of print. J Am Acad Dermatol. 2025. PMID: 40967307
Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.
Cai L, Li C, Li S, Zhang X, Wang G, Yu J, Huang K, Fang H, Ding Y, Wang J, Jiang C, Lu Q, Tao J, Zhang J. Cai L, et al. Dermatol Ther (Heidelb). 2025 Oct;15(10):2817-2818. doi: 10.1007/s13555-025-01480-5. Dermatol Ther (Heidelb). 2025. PMID: 40705212 Free PMC article. No abstract available.
Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study.
Xia L, Miao G, Yang X, Li Y, Liang Y, Li Y, Li L, Ma L, Zhang F, Chen R, Duan X, Wang L, Feng Y, Li Z, Lu F, Wang J, Guo S, Zhao J, Wu L, Cui Y, Li S, Ji C, Li X, Lei T, Fan J, Gao X. Xia L, et al. J Am Acad Dermatol. 2025 Jul;93(1):115-123. doi: 10.1016/j.jaad.2025.03.018. Epub 2025 Apr 10. J Am Acad Dermatol. 2025. PMID: 40208132 Free article. Clinical Trial.
1,899 results